Sellbyville, DE -- (SBWIRE) -- 11/13/2018 -- The U.S. Compounding Pharmacies Market to exceed USD 7 billion by 2025; according to a new research report by Global Market Insights, Inc. Growing prevalence of chronic diseases in the U.S. such as cancer, diabetes, cardiovascular disease, respiratory diseases and obesity will drive the U.S. compounding pharmacies market growth over the forecast period. Increasing drug shortage in the country due to production delays and unavailability of previously manufactured drugs in the market will surge the demand of compounded drugs. Timely availability of compounded drugs in the treatment of cardiac or other emergency conditions will thus foster the U.S. compounding pharmacies industry growth.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2961

Non-sterile segment held the highest share of 67.7% in 2017 owing to increasing adoption of oral medication that offers convenience and ease of administration in patients of all age groups. Growing demand for oral liquid preparation and topical medication for pain management and anti-inflammatory therapies will further propel segment growth. Topical product segment is estimated to witness 5.3% CAGR over the analysis timeframe owing to increasing demand for topically administered drugs such as muscle relaxants, anti-inflammatories and anesthetics prescribed for pain management and inflammation therapy.

Pediatric application segment held 14.5% market share in 2017 and is estimated to grow significantly during the forthcoming years. Ability of compounding pharmacies to transform standard drugs into flavored dosage and colorful forms will increase its acceptance among the children thereby accelerating the segmental growth. Pharmaceutical ingredient alteration (PIA) segment accounted for USD 1.7 billion in 2017 owing to rising demand for drugs compounded in accordance with specific patient needs such as hypoallergenic versions of drugs for individuals allergic to certain dyes or preservatives.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
- Braun Medical
- Fresenius Kabi
- Fagron
- Cantrell Drug Company, Inc.
- Clinigen Group
- Dougherty's Pharmacy, Inc.
- McKesson Corporation
- Nephron Pharmaceuticals
- Pentec Health
- PharMEDium Services
- Wells Pharmacy Network

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2961

503A compounding pharmacy segment accounted for a considerable revenue share of USD 2.3 billion in 2017. The growth is attributable to the ability of 503A pharmacies to compound sterile and non-sterile medications in-house, as per the patient-specific needs based on the prescription. However, high cost involved in compounding as well as continuous changes in the regulatory scenario pertaining to 503A compounding pharmacies may limit the segmental growth in the foreseeable future.

503B compounding pharmacy segment is estimated to show lucrative CAGR of 7.2% during the forthcoming years. 503B pharmacies are outsourcing facilities that manufacture large batches with or without prescription that are sold to healthcare facilities for office use. Large batch production of compounded drugs resulting in lower manufacturing costs will fuel the 503B compounding pharmacies market throughout the analysis period.